Showing 381 - 400 results of 6,700 for search 'significantly ((((((largest decrease) OR (larger decrease))) OR (teer decrease))) OR (we decrease))', query time: 0.59s Refine Results
  1. 381

    Fig 18 in each curve fitting results. by Zhezhe Zhang (19704587)

    Published 2024
    “…Under the same <i>JRC</i>, σ<sub><i>i</i></sub> increases with the increase of τ<sub>1</sub>, and Δσ<sub>n</sub> decreases with the increasing τ<sub>1</sub>. Under the same <i>JRC</i> and σ<sub><i>i</i></sub>, τ<sub><i>i</i></sub> is significantly smaller under the UNLCSL path than the CNL path. …”
  2. 382

    Fig 29 in each curve fitting results. by Zhezhe Zhang (19704587)

    Published 2024
    “…Under the same <i>JRC</i>, σ<sub><i>i</i></sub> increases with the increase of τ<sub>1</sub>, and Δσ<sub>n</sub> decreases with the increasing τ<sub>1</sub>. Under the same <i>JRC</i> and σ<sub><i>i</i></sub>, τ<sub><i>i</i></sub> is significantly smaller under the UNLCSL path than the CNL path. …”
  3. 383

    Fig 9(b) in the straight-line fitting results. by Zhezhe Zhang (19704587)

    Published 2024
    “…Under the same <i>JRC</i>, σ<sub><i>i</i></sub> increases with the increase of τ<sub>1</sub>, and Δσ<sub>n</sub> decreases with the increasing τ<sub>1</sub>. Under the same <i>JRC</i> and σ<sub><i>i</i></sub>, τ<sub><i>i</i></sub> is significantly smaller under the UNLCSL path than the CNL path. …”
  4. 384

    Specimen packaging process. by Zhezhe Zhang (19704587)

    Published 2024
    “…Under the same <i>JRC</i>, σ<sub><i>i</i></sub> increases with the increase of τ<sub>1</sub>, and Δσ<sub>n</sub> decreases with the increasing τ<sub>1</sub>. Under the same <i>JRC</i> and σ<sub><i>i</i></sub>, τ<sub><i>i</i></sub> is significantly smaller under the UNLCSL path than the CNL path. …”
  5. 385

    Relationship between τ<sub><i>i</i></sub> and σ<sub><i>i</i></sub>. by Zhezhe Zhang (19704587)

    Published 2024
    “…Under the same <i>JRC</i>, σ<sub><i>i</i></sub> increases with the increase of τ<sub>1</sub>, and Δσ<sub>n</sub> decreases with the increasing τ<sub>1</sub>. Under the same <i>JRC</i> and σ<sub><i>i</i></sub>, τ<sub><i>i</i></sub> is significantly smaller under the UNLCSL path than the CNL path. …”
  6. 386

    The relationship between Δσ<sub>n</sub> and τ<sub>1</sub>, <i>JRC</i>. by Zhezhe Zhang (19704587)

    Published 2024
    “…Under the same <i>JRC</i>, σ<sub><i>i</i></sub> increases with the increase of τ<sub>1</sub>, and Δσ<sub>n</sub> decreases with the increasing τ<sub>1</sub>. Under the same <i>JRC</i> and σ<sub><i>i</i></sub>, τ<sub><i>i</i></sub> is significantly smaller under the UNLCSL path than the CNL path. …”
  7. 387

    Relationship between τ<sub><i>i</i></sub> and σ<sub><i>i</i></sub>. by Zhezhe Zhang (19704587)

    Published 2024
    “…Under the same <i>JRC</i>, σ<sub><i>i</i></sub> increases with the increase of τ<sub>1</sub>, and Δσ<sub>n</sub> decreases with the increasing τ<sub>1</sub>. Under the same <i>JRC</i> and σ<sub><i>i</i></sub>, τ<sub><i>i</i></sub> is significantly smaller under the UNLCSL path than the CNL path. …”
  8. 388
  9. 389
  10. 390
  11. 391

    Flowchart of the screening process. by Huixia Ren (500186)

    Published 2025
    “…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
  12. 392

    Result of the AMSTAR-2 assessments. by Huixia Ren (500186)

    Published 2025
    “…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
  13. 393

    Characteristics of included reviews. by Huixia Ren (500186)

    Published 2025
    “…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
  14. 394

    Result of the PRISMA assessments. by Huixia Ren (500186)

    Published 2025
    “…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
  15. 395

    Result of the ROBIS assessments. by Huixia Ren (500186)

    Published 2025
    “…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
  16. 396

    Cohort characteristics. by Vincent Pey (21433304)

    Published 2025
    “…</p><p>Results</p><p>Upon initiation of CPB we observed a significant decrease in arterial whole blood redox potential (101.90 mV + /- 11.52 vs. 41.80 mV + /- 10,26; p < 0.0001). …”
  17. 397

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    “…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”
  18. 398

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    “…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”
  19. 399

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    “…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”
  20. 400

    Analytical framework and statistical methods. by Na Chen (153323)

    Published 2024
    “…Our findings reveal significant variations in income insecurity and social protection responses across these groups. the pandemic had a significant impact on household incomes globally, with lower-middle-income countries experiencing the most significant income reductions. …”